IE44943B1 - Tumor antigen and process for the preparation thereof - Google Patents
Tumor antigen and process for the preparation thereofInfo
- Publication number
- IE44943B1 IE44943B1 IE887/77A IE88777A IE44943B1 IE 44943 B1 IE44943 B1 IE 44943B1 IE 887/77 A IE887/77 A IE 887/77A IE 88777 A IE88777 A IE 88777A IE 44943 B1 IE44943 B1 IE 44943B1
- Authority
- IE
- Ireland
- Prior art keywords
- tumour
- group
- supernatant
- pharmaceutical preparation
- lysolecithin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 49
- 239000000427 antigen Substances 0.000 title claims abstract description 35
- 102000036639 antigens Human genes 0.000 title claims abstract description 35
- 108091007433 antigens Proteins 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 33
- 230000008569 process Effects 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 23
- 239000006228 supernatant Substances 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims abstract description 14
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 239000006285 cell suspension Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical group OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 claims description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 3
- 229950004354 phosphorylcholine Drugs 0.000 claims description 3
- 238000004062 sedimentation Methods 0.000 claims description 3
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoserine Chemical group OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000013049 sediment Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000005373 porous glass Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011735 C3H mouse Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19762619715 DE2619715A1 (de) | 1976-05-04 | 1976-05-04 | Tumor-antigen und verfahren zu dessen herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE44943L IE44943L (en) | 1977-11-04 |
| IE44943B1 true IE44943B1 (en) | 1982-05-19 |
Family
ID=5977057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE887/77A IE44943B1 (en) | 1976-05-04 | 1977-05-03 | Tumor antigen and process for the preparation thereof |
Country Status (17)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551532A (en) * | 1980-05-08 | 1985-11-05 | Takeda Chemical Industries, Ltd. | Ethylene glycol derivatives having anti-protozoan, anti-fungal and anti-tumor activity |
| US4444766A (en) * | 1980-10-21 | 1984-04-24 | Boehringer Mannheim Gmbh | Sulfur-containing phospholipid compounds and therapeutic compositions |
| JPS5772914A (en) * | 1980-10-22 | 1982-05-07 | Takeda Chem Ind Ltd | Antitumor agent |
| JPS58138383A (ja) * | 1982-02-13 | 1983-08-17 | Nippon Shinyaku Co Ltd | 生理活性物質の製法 |
| US4562179A (en) * | 1982-04-19 | 1985-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Phospholipid derivatives, and pharmaceutical composition of the same |
| JPS5933223A (ja) * | 1982-08-20 | 1984-02-23 | Koken Kk | 人の悪性腫瘍細胞増殖抑制剤 |
| JPS6081194A (ja) * | 1983-10-11 | 1985-05-09 | Takeda Chem Ind Ltd | ケトアルキルリン脂質 |
| JP2561478B2 (ja) * | 1986-07-22 | 1996-12-11 | 武田薬品工業株式会社 | グリセリン誘導体 |
| US5030733A (en) * | 1987-07-23 | 1991-07-09 | Hoechst-Roussel Pharmaceticals Incorporated | Hydroxy-, alkoxy- and benzyloxy-substituted phospholipids |
| US5145844A (en) * | 1987-07-23 | 1992-09-08 | Hoechst-Roussel Pharmaceuticals Incorporated | Methods of using hydroxy-, alkoxy- and benzyloxy-substituted phospholipids to treat phospholipase A2 -mediated conditions and to alleviate pain |
| US5036152A (en) * | 1988-03-10 | 1991-07-30 | Hoechst-Roussel Pharmaceuticals Incorporated | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids |
| US4888328A (en) * | 1988-03-10 | 1989-12-19 | Hoeschst-Roussel Incorporated | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids |
| DE3906952A1 (de) * | 1989-03-04 | 1990-09-06 | Boehringer Mannheim Gmbh | (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel |
-
1976
- 1976-05-04 DE DE19762619715 patent/DE2619715A1/de not_active Withdrawn
-
1977
- 1977-04-29 NL NL7704724A patent/NL7704724A/xx not_active Application Discontinuation
- 1977-05-02 SE SE7705070A patent/SE7705070L/xx unknown
- 1977-05-02 IL IL51989A patent/IL51989A/xx unknown
- 1977-05-02 IT IT23093/77A patent/IT1074325B/it active
- 1977-05-02 NZ NZ183980A patent/NZ183980A/xx unknown
- 1977-05-03 AU AU24818/77A patent/AU517395B2/en not_active Expired
- 1977-05-03 CA CA277,457A patent/CA1077840A/en not_active Expired
- 1977-05-03 AT AT313277A patent/AT362497B/de not_active IP Right Cessation
- 1977-05-03 LU LU77245A patent/LU77245A1/xx unknown
- 1977-05-03 GB GB18430/77A patent/GB1575545A/en not_active Expired
- 1977-05-03 IE IE887/77A patent/IE44943B1/en unknown
- 1977-05-03 DK DK194477A patent/DK194477A/da not_active Application Discontinuation
- 1977-05-04 BE BE177279A patent/BE854269A/xx not_active IP Right Cessation
- 1977-05-04 FR FR7713521A patent/FR2391733A1/fr active Granted
- 1977-05-04 JP JP5194377A patent/JPS52134011A/ja active Pending
- 1977-05-05 ZA ZA00772648A patent/ZA772648B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK194477A (da) | 1977-11-05 |
| IL51989A0 (en) | 1977-07-31 |
| AU517395B2 (en) | 1981-07-30 |
| FR2391733B1 (enrdf_load_stackoverflow) | 1980-03-07 |
| AU2481877A (en) | 1978-11-09 |
| AT362497B (de) | 1981-05-25 |
| ATA313277A (de) | 1980-10-15 |
| CA1077840A (en) | 1980-05-20 |
| LU77245A1 (enrdf_load_stackoverflow) | 1977-12-13 |
| NL7704724A (nl) | 1977-11-08 |
| SE7705070L (sv) | 1977-11-05 |
| JPS52134011A (en) | 1977-11-09 |
| ZA772648B (en) | 1978-04-26 |
| IE44943L (en) | 1977-11-04 |
| NZ183980A (en) | 1980-04-28 |
| FR2391733A1 (fr) | 1978-12-22 |
| IT1074325B (it) | 1985-04-20 |
| GB1575545A (en) | 1980-09-24 |
| BE854269A (fr) | 1977-11-04 |
| DE2619715A1 (de) | 1977-11-24 |
| IL51989A (en) | 1980-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spiess et al. | In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2 | |
| IE44943B1 (en) | Tumor antigen and process for the preparation thereof | |
| US20150202229A1 (en) | Method for Inducing Immune Stimulation Using Non-Proliferative Allogeneic Leukocytes | |
| JP2003511398A (ja) | 移植における免疫応答の予防および処置に用いる抑制細胞 | |
| JPH06508613A (ja) | 自己移植の改良法 | |
| US4931275A (en) | Anti-tumor vaccines and their preparation | |
| US4013788A (en) | Watersoluble extracts of corynebacteria, process for obtaining them and their use | |
| CA1280693C (en) | Purification of pertussis antigens | |
| Tavaf et al. | Effects of immune system cells in GvHD and corresponding therapeutic strategies | |
| Vischer | Mitogenic factors produced by lymphocyte activation: effect on T-and B-cells | |
| JP2021516052A (ja) | 胸腺組織に由来する制御性ｔ細胞を入手する方法および免疫系障害における細胞免疫療法としての前記細胞の使用 | |
| EP0202947A2 (en) | Vaccine production | |
| EP0080021B1 (en) | Haemophilus influenzae type b and pertussis outer membrane component combined vaccine | |
| US4341697A (en) | Antigenic material | |
| JPH04501853A (ja) | 大型多価免疫原 | |
| US20190060368A1 (en) | Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles And Uses Thereof In Autoimmune Diseases | |
| US4009257A (en) | Preparation of immunosuppressive materials | |
| FI63674B (fi) | Foerfarande foer isolering och rening av immunologiskt aktivt polyribosylribitolfosfat | |
| US4728637A (en) | Complex of macromolecules extracted from mesenchymal cells for treating chronic degenerative disease | |
| AU772142B2 (en) | Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (GCS) | |
| US4288557A (en) | Antigenic complex from N. gonorrhoeae | |
| Singh et al. | Effect of xenogeneic immune RNA on normal human lymphocytes against human osteosarcoma cells in vitro | |
| JPH09509649A (ja) | 免疫化同種異系骨髄ドナーからの活性腫瘍特異的免疫化の移入のための方法および組成物 | |
| EP0002645B1 (en) | Antigenic complex from neisseria gonorrhoeae, process and vaccine | |
| Ezaki et al. | Active specific immunization with allogeneic leukemia associated antigens or irradiated allogeneic leukemia cells in acute leukemia |